Search results
Cardiogenic Shock in Restrictive Cardiomyopathies
Added:
7 months ago
Review Article
Added:
11 months ago
ACC 25 - FRESH-UP shows liberal fluid intake did not result in a significant difference in health status compared to fluid restriction of 1500ml per day, but did result in a lower perceived thirst distress.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Roland Van Kimmenade (Radboud University Medical Center, Nijmegen, NL) to discuss the findings from the multi-center,…
View more
Added:
1 year ago
ACC.24 — Dr Andrew P DeFilipis (Vanderbilt University Medical Center, US) joins us onsite at ACC to discuss the findings from a subgroup analysis of the MINT Trial (NCT02981407).MINT is a randomised parallel assignment trial which aims to compare liberal and restrictive blood cell transfusion strategies in patients who have had an acute myocardial infarction (AMI) and are anaemic. Findings were…
View more
Added:
5 months ago
HFSA 2025 - Post hoc analysis of ATTRibute-CM reveals significant reduction in cardiovascular mortality and death after 30 months of acoramidis in patients with ATTR-CM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss a post hoc exploratory analysis from the ATTRibute-CM trial examining the timing and magnitude of cardiovascular outcome reductions with acoramidis in…
View more
Added:
1 week ago
Source:
Radcliffe Cardiology
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease associated with a significant burden of recurrent cardiovascular (CV) events. A new post hoc analysis of the ATTRibute-CM trial suggests that acoramidis, an oral transthyretin (TTR) stabiliser, significantly reduces the cumulative burden of these outcomes.¹MethodologyThis exploratory analysis used data from the phase 3,…
View more
Novel Therapies in ATTR-CM
Added:
4 months ago
Review Article
Added:
2 years ago
Prof Marianna Fontana (University College London, UK) joined us to discuss the discovery and impact of antibody-associated reversal of ATTR amyloidosis–related cardiomyopathy in three patients.
Prof Fontana and her team, in a correspondence published in The New England Journal of Medicine, revealed the identification of an antibody linked to the spontaneous reversal of cardiac transthyretin…
View more
Added:
2 years ago
ESC 2023 — Prof Julian Gillmore (University College London, UK) joins us onsite to discuss the findings of the ATTRibute-CM Study (NCT03860935).
ATTRibute-CM was a randomised double-blind trial which aimed to evaluate the safety and efficacy of acoramidis in a cohort of patients diagnosed with transtherytin amyloid cardiomyopathy (ATTR-CM). 632 patients were enrolled in the trial, and were…
View more
Added:
3 weeks ago
Source:
Radcliffe Cardiology
A new study has revealed significant delays in the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) following an initial diagnosis of heart failure (HF), with the median time to diagnosis exceeding one year.¹ Timely identification of ATTR-CM is critical to reduce morbidity and mortality, as effective treatments are available.²MethodologyThis retrospective cohort study analysed data…
View more
Added:
1 year ago
AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).Dr Fontana discusses a phase 1, ongoing, open-label, single…
View more